KLTO

Klotho Neurosciences

0.5162 USD
--0.0084
1.6%
At close Updated Oct 29, 4:00 PM EDT
Pre-market
After hours
0.5100
--0.0062
1.2%
1 day
-1.6%
5 days
-0.31%
1 month
2.02%
3 months
-46.23%
6 months
203.65%
Year to date
-26.2%
1 year
1.12%
5 years
-94.78%
10 years
-94.78%
 

About: Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.

Employees: 3

0
Funds holding %
of 7,502 funds
Analysts bullish %
0
Positive news %
Price charts implemented using Lightweight Charts™